Cytotect CP(R) Biotest activates immune cells that are crucial to control Cytomegalovirus
- Cytomegalovirus (CMV) leads to severe complications in immunocompromised patients, particularly after transplantation
- Antiviral drugs suppress the production of new CMV particles in infected patients, but do not prevent initial infection of healthy cells nor do they support the patient's immune system
- Results from a new study show that Cytotect CP(R) Biotest can stimulate CMV-specific immunity, in addition to its antiviral effects such as virus neutralization
Dreieich, 16 November 2021. Cytomegalovirus is the most common viral infection after transplantation. CMV infection causes significant morbidity and mortality in immunosuppressed solid organ and stem cell transplant recipients. Cytotect CP(R) Biotest contains specific antibodies that neutralize CMV. As such, it is used in those highly immunosuppressed patients to protect them from the detrimental effects of this virus. Additionally, it was described that Cytotect CP(R) Biotest can have immunomodulatory properties, e.g. by reducing organ rejection, potentially by inhibiting overshooting immune responses in the inflammatory milieu of transplant patients.
A new scientific publication by Deml and colleagues indicates that Biotest's CMV hyperimmunoglobulin product Cytotect CP(R) Biotest has various beneficial effects on patients suffering from CMV infection. The study, which was supported by Biotest AG, analysed CMV-positive and CMV-negative blood donors and their immune response towards CMV.
The new data shows that Cytotect CP(R) Biotest is able to activate different immune cells. This includes also the activation of cytotoxic T lymphocytes by CMV, which may happen via an immunological process termed cross-presentation. In this study, the effect was more prominent when Cytotect CP(R) Biotest was used and - importantly - this was also observed in presence of immunosuppressive drugs, which are part of the standard treatment regimen of patients after transplantation.
"Altogether, this study demonstrates that, in addition to the transfer of passive humoral immunity, the use of Cytotect CP(R) Biotest in transplantation might promote a stronger and faster cellular response to CMV infection and thus contribute to CMV prophylaxis." states Dr Christian Hüber, Senior Manager Corporate Medical Affairs from Biotest. Interestingly, the new data are well in line with new findings from researchers in the United Kingdom who have recently shown that Cytotect CP(R) Biotest is able to promote the activation of natural killer cells via a mechanism called antibody-dependent cellular cytotoxicity. Although they observed such an effect also with experimental monoclonal antibodies, it was most prominent when the commercially available and approved product Cytotect CP(R) Biotest was used in their experiments.
Biotest AG welcomes these new data and considers to support additional studies looking into the mode of action of Cytotect CP(R) Biotest as well as other hyperimmunoglobulin products.
About Cytotect CP(R) Biotest
Cytotect CP(R) Biotest is a cytomegalovirus-specific hyperimmunoglobulin preparation with a high antibody titre against CMV. The product is approved for prophylaxis of clinical manifestations of CMV infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients. The concomitant use of adequate virostatic agents should be considered for CMV-prophylaxis. Cytotect CP(R) Biotest is also marketed as Megalotect(R), Megalotect CP(R), Cytomegatect(R) and NeoCytotect(R) in different countries.
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.
Dr Monika Buttkereit
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
 Deml, L., et al., Stimulatory Effect of CMV Immunoglobulin on Innate Immunity and on the Immunogenicity of CMV Antigens. Transplant Direct, 2021. 7(11): p. e781.
 Vlahava, V.M., et al., Monoclonal antibodies targeting nonstructural viral antigens can activate ADCC against human cytomegalovirus. J Clin Invest, 2021. 131(4).
16.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de